BELLEROPHON would like to make a call for the process development and production in E. coli according to Good Manufacturing Practice (GMP) of a protein vaccine candidate to be used in toxicological and phase I studies. The subcontracting is expected in Q4 2015.
PHARVAT is a European Commission (EC) Seventh Framework Programme (FP7) funded project aiming to generate a harmonised procedure to permit pre-clinical selection of vaccine adjuvants. The project is running for a two year period and was initiated in November 2009 with an overall budget of € 300 000.
The annual meeting of MVVC / MVVC 2 held in Oxford in March is mentioned in the EDCTP May news letter (page 6). Field trials of a new combination malaria vaccine, which are an integral part of the MVVC2 project, are funded by among others EDCTP.
Want to learn more about what EVI is doing, then join us for the 2015 Rendez-Vous on 9 December.
It is an increasing popular event, bringing together people from all corners of the scientific community, the European Commission and other like funders.